XPO1 and prostate cancer: These screens identified multiple therapeutic vulnerabilities of Snail+ prostate cancer cells, including several with known functions in prostate cancer and/or EMT, such as aurora kinases (Beltran et al., 2011; Kivinummi et al., 2017; Beltran et al., 2019), MET (Chu et al., 2014; Lucas et al., 2014), polo-like kinases (Weichert et al., 2004; Liu et al., 2011; Deeraksa et al., 2013), and CRM1/XPO1 (Gravina et al., 2017; Wei et al., 2018).